Citigroup Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $342
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebovitz maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $291 to $342.
August 02, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst David Lebovitz maintains a Buy rating on Alnylam Pharmaceuticals and raises the price target from $291 to $342.
The raised price target and maintained Buy rating from a reputable analyst at Citigroup is likely to positively impact Alnylam Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100